Drugs With Only 1 Patent Left for Expiry
As certain drugs approach the end of their patent protection, they enter a critical phase where only one patent remains before generic versions can enter the market. This final patent is all that stands between these drugs and potential competition, which could lead to lower prices and greater accessibility. On this page, we highlight the drugs that are down to their last patent, signaling that major changes could be on the way for these medications and their availability.
1. ADASUVE
Adasuve is a brand drug owned by Alexza Pharmaceuticals Inc.
It is used for managing acute agitation in adults with schizophrenia or bipolar I disorder. It was approved for market use on Dec 21, 2012. Adasuve uses Loxapine as an active ingredient.
Total Patents: 18
Remaining 1 active patent -
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry |
|---|---|---|
| US8387612 | Self-contained heating unit and drug-supply unit employing same | Oct 23, 2026 |
Check the entire list of patents and their expiration dates for Adasuve
2. ADDYI
Addyi is a brand drug owned by Sprout Pharmaceuticals Inc.
It is Used for treating hypoactive sexual desire disorder (HSDD). It was approved for market use on Aug 18, 2015. Addyi uses Flibanserin as an active ingredient.
Total Patents: 4
Remaining 1 active patent -
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry |
|---|---|---|
| US7151103 | Method of treating female hypoactive sexual desire disorder with flibanserin | May 09, 2028 |
Check the entire list of patents and their expiration dates for Addyi
3. ALTABAX
Altabax is a brand drug owned by Almirall Llc.
It is Used for treating impetigo caused by Staphylococcus aureus or Streptococcus pyogenes. It was approved for market use on Apr 12, 2007. Altabax uses Retapamulin as an active ingredient.
Total Patents: 4
Remaining 1 active patent -
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry |
|---|---|---|
| US7875630 | Process salts compositions and use | Feb 14, 2027 |
Check the entire list of patents and their expiration dates for Altabax
4. ANGELIQ
Angeliq is a brand drug owned by Bayer Healthcare Pharmaceuticals Inc.
It was approved for market use on Feb 29, 2012. Angeliq uses Drospirenone; Estradiol as an active ingredient.
Total Patents: 2
Remaining 1 active patent -
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry |
|---|---|---|
| US8906890 | Very low-dosed solid oral dosage forms for HRT | Oct 22, 2031 |
Check the entire list of patents and their expiration dates for Angeliq
5. APRISO
Apriso is a brand drug owned by Salix Pharmaceuticals Inc.
It is Used for maintaining remission of ulcerative colitis in adults. It was approved for market use on Oct 31, 2008. Apriso uses Mesalamine as an active ingredient.
Total Patents: 7
Remaining 1 active patent -
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry |
|---|---|---|
| US8865688 | Compositions and methods for treatment of bowel diseases with granulated mesalamine | May 01, 2030 |
Check the entire list of patents and their expiration dates for Apriso
6. ARICEPT
Aricept is a brand drug owned by Eisai Inc.
It was approved for market use on Jul 23, 2010. Aricept uses Donepezil Hydrochloride as an active ingredient.
Total Patents: 4
Remaining 1 active patent -
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry |
|---|---|---|
| US8481565 | Method for stabilizing anti-dementia drug | Oct 04, 2026 |
Check the entire list of patents and their expiration dates for Aricept
7. ATROVENT HFA
Atrovent Hfa is a brand drug owned by Boehringer Ingelheim Pharmaceuticals Inc.
It was approved for market use on Nov 27, 2004. Atrovent Hfa uses Ipratropium Bromide as an active ingredient.
Total Patents: 5
Remaining 1 active patent -
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry |
|---|---|---|
| US8474447 | Inhaler device | Jan 17, 2030 |
Check the entire list of patents and their expiration dates for Atrovent Hfa
8. BALCOLTRA
Balcoltra is a brand drug owned by Avion Pharmaceuticals Llc.
It is Used for treating iron deficiency. It was approved for market use on Jan 9, 2018. Balcoltra uses Ethinyl Estradiol; Levonorgestrel as an active ingredient.
Total Patents: 2
Remaining 1 active patent -
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry |
|---|---|---|
| US7838042 | Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions | Jun 01, 2027 |
Check the entire list of patents and their expiration dates for Balcoltra
9. BEPREVE
Bepreve is a brand drug owned by Bausch And Lomb Inc.
It was approved for market use on Sep 8, 2009. Bepreve uses Bepotastine Besilate as an active ingredient.
Total Patents: 3
Remaining 1 active patent -
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry |
|---|---|---|
| US8784789 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations | Jan 13, 2025 |
Check the entire list of patents and their expiration dates for Bepreve